ATXI Overview

Avenue Therapeutics and Baergic Bio Deal: Avenue Therapeutics has agreed to sell its majority-owned subsidiary Baergic Bio to Axsome Therapeutics, which includes global rights to the epilepsy treatment AXS-17 (formerly BAER-101).

Financial Terms of the Agreement: The deal involves an upfront payment of $0.3M, potential development and sales milestone payments totaling up to $81.5M, and tiered royalties, with Avenue Therapeutics set to receive approximately 74% of future payments and royalties.

Axsome Therapeutics' Market Strategy: Axsome anticipates enhanced market access for its products SYMBRAVO and AUVELITY while continuing to advance its late-stage pipeline.

Axsome's Financial Performance: In its Q3 2025 earnings report, Axsome reported a GAAP EPS of -$0.94, which missed expectations, but its revenue of $171M exceeded forecasts by $8.01M.

U.S. Stock Market Performance: U.S. stocks fell this morning, with the Dow Jones down approximately 200 points and significant declines in consumer discretionary shares, while energy shares saw a slight increase.

Economic Indicators: U.S. industrial production rose by 0.7% in February, exceeding expectations, while housing starts surged by 11.2%. However, building permits declined by 1.2%, and import prices increased by 0.4%.

Harrow, Inc. Stock Surge: Harrow, Inc. shares rose 23.1% in pre-market trading after announcing its fourth quarter and year-end 2024 financial results along with 2025 revenue guidance.

Pre-Market Trading Movements: Several stocks experienced significant changes in pre-market trading, with Regencell Bioscience Holdings gaining 45.7% and Avenue Therapeutics falling 40.3%.

Earnings Release: AVENUE THERAPEUTICS is set to announce its quarterly earnings on March 17th, with analysts predicting $0 in revenue and a loss of -$0.58 per share.

Insider Trading Activity: In the past six months, insiders have made four trades of $ATXI stock, with an equal number of purchases and sales, while institutional investors have shown mixed activity by adding and reducing their holdings.

Analyst Rating: Jason McCarthy from Maxim Group has maintained a Buy rating on Avenue Therapeutics (ATXI), which closed at $1.93, while the company reported a quarterly GAAP net loss of $2.69 million compared to a profit last year.

Company Overview: Avenue Therapeutics focuses on developing intravenous tramadol for post-operative pain management and has a Moderate Buy analyst consensus rating according to TipRanks.

Corporate Developments: Avenue Therapeutics reported progress in its clinical trials, particularly for AJ201 aimed at treating spinal and bulbar muscular atrophy, with topline data expected by year-end 2024. The company also plans to initiate a Phase 2a trial for BAER-101 targeting epilepsy and has finalized plans for a Phase 3 study of IV tramadol for post-operative pain management.

Financial Overview: As of September 30, 2024, Avenue Therapeutics had $2.6 million in cash, down from $4.9 million in the previous quarter, while research and development expenses rose significantly to $2.3 million compared to $0.9 million in Q3 2023, resulting in a net loss of $3.1 million for the quarter.